ALZHEIMER’S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023
(Adnkronos) – AMSTERDAM, July 17, 2023 /PRNewswire/ — The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer’s disease demonstrate an important advancement in
